Vidac Pharma Holding PLC: Vidac Pharma Publishes Unaudited Interim Financial Statements for the First Half of 2026
London (pta021/29.09.2026/15:00 UTC+2)
Vidac Pharma Holding PLC announces the publication of its Unaudited Condensed Consolidated Interim Financial Statements for the six months ended 30 June 2026.
The interim financial statements are available on the Company's website at:
https://vidacpharma.com/docs/ir/interim-report-h1-2026.pdf
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company developing first-in-class therapies designed to reverse the abnormal metabolism of cancer cells by targeting the interaction between hexokinase 2 (HK2) and VDAC1. The Company's lead drug candidate, VDA-1102, is being developed as a topical treatment for actinic keratosis and has also been evaluated in cutaneous T-cell lymphoma (CTCL). Vidac Pharma is also developing VDA-1275, an orally administered drug candidate for systemic oncology indications.
(end)
| Emitter: |
Vidac Pharma Holding PLC 20-22 Wenlock Road N1 7GU London United Kingdom |
|
|---|---|---|
| Contact Person: | Sandra Gamzon | |
| Phone: | +972 544 999951 | |
| E-Mail: | investors@vidacpharma.com | |
| Website: | www.vidacpharma.com | |
| ISIN(s): | GB00BM9XQ619 (Share) | |
| Stock Exchange(s): | Free Market in Dusseldorf (Primärmarkt), Hamburg, Stuttgart | |
| Other Stock Exchanges: | XETRA |